Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q2 EPS

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Anterix Inc. (ATEX) Tops Q4 EPS by 152c
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance